Impact of V9302, a Competitive Antagonist of Transmembrane Glutamine Flux on Reversal of Resistance in Breast Cancer Cell Lines

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2024 Jul 27

PMID 39065573

Authors

Nikoletta Szemeredi

Zsuzsanna Schelz

Daria Antonia Horvath

Balint Racz

Andras G Szatmari

Hiba F Muddather

Noemi Bozsity

Istvan Zupko

Gabriella Spengler

Affiliations

Soon will be listed here.

Abstract

Chemotherapy is a known treatment modality that improves the long-term survival of breast cancer patients. However, due to the resistance to numerous anticancer drugs, alternative chemotherapeutic strategies are required. Regarding antimetabolic drugs, several compounds have proven anticancer properties, such as statins. The present study aimed to investigate the in vitro effects of V9302, a competitive antagonist of glutamine flux, on different subtypes of breast cancers (estrogen, progesterone, and HER2 receptor-positive or negative, and Pgp-negative and Pgp-overexpressing). The interactions of V9302 with standard chemotherapeutic drugs (doxorubicin and cisplatin) were also determined by MTT staining on breast cancer cell lines. Furthermore, the influence of V9302 on the cell cycle of MCF-7 and its Pgp-overexpressing counterpart KCR was monitored by flow cytometry. It was shown that V9302 exerted synergistic interactions with doxorubicin in all breast cancer cell lines. In cell cycle analysis, the KCR cell line was more sensitive to V9302. After 48 h, cell proliferation was completely blocked, and elevated G1, suppressed S, and decreased G2/M could be detected. Inhibition of glutamate transport can be assumed to block resistance related to Pgp.

References

Gennari A, Andre F, Barrios C, Cortes J, de Azambuja E, DeMichele A . ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021; 32(12):1475-1495. DOI: 10.1016/j.annonc.2021.09.019. View

Peng R, Dong Y, Zheng M, Kang H, Wang P, Zhu M . IL-17 promotes osteoclast-induced bone loss by regulating glutamine-dependent energy metabolism. Cell Death Dis. 2024; 15(2):111. PMC: 10844210. DOI: 10.1038/s41419-024-06475-2. View

Catalano A, Iacopetta D, Ceramella J, Scumaci D, Giuzio F, Saturnino C . Multidrug Resistance (MDR): A Widespread Phenomenon in Pharmacological Therapies. Molecules. 2022; 27(3). PMC: 8839222. DOI: 10.3390/molecules27030616. View

Sleire L, Forde H, Netland I, Leiss L, Skeie B, Enger P . Drug repurposing in cancer. Pharmacol Res. 2017; 124:74-91. DOI: 10.1016/j.phrs.2017.07.013. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Colditz G, Bohlke K . Priorities for the primary prevention of breast cancer. CA Cancer J Clin. 2014; 64(3):186-94. DOI: 10.3322/caac.21225. View

Zhu H, Liu G . Glutamate up-regulates P-glycoprotein expression in rat brain microvessel endothelial cells by an NMDA receptor-mediated mechanism. Life Sci. 2004; 75(11):1313-22. DOI: 10.1016/j.lfs.2004.02.027. View

Cripe L, Uno H, Paietta E, Litzow M, Ketterling R, Bennett J . Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999. Blood. 2010; 116(20):4077-85. PMC: 2993615. DOI: 10.1182/blood-2010-04-277269. View

Kobayashi S, Sugiura H, Ando Y, Shiraki N, Yanagi T, Yamashita H . Reproductive history and breast cancer risk. Breast Cancer. 2012; 19(4):302-8. PMC: 3479376. DOI: 10.1007/s12282-012-0384-8. View

10.

Chang-Claude J, Andrieu N, Rookus M, Brohet R, Antoniou A, Peock S . Age at menarche and menopause and breast cancer risk in the International BRCA1/2 Carrier Cohort Study. Cancer Epidemiol Biomarkers Prev. 2007; 16(4):740-6. DOI: 10.1158/1055-9965.EPI-06-0829. View

11.

. Global cancer burden growing, amidst mounting need for services. Saudi Med J. 2024; 45(3):326-327. PMC: 11115397. View

12.

Chou T . Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev. 2006; 58(3):621-81. DOI: 10.1124/pr.58.3.10. View

13.

Weth F, Hoggarth G, Weth A, Paterson E, White M, Tan S . Unlocking hidden potential: advancements, approaches, and obstacles in repurposing drugs for cancer therapy. Br J Cancer. 2023; 130(5):703-715. PMC: 10912636. DOI: 10.1038/s41416-023-02502-9. View

14.

Howell A, Anderson A, Clarke R, Duffy S, Evans D, Garcia-Closas M . Risk determination and prevention of breast cancer. Breast Cancer Res. 2014; 16(5):446. PMC: 4303126. DOI: 10.1186/s13058-014-0446-2. View

15.

van Geldermalsen M, Wang Q, Nagarajah R, Marshall A, Thoeng A, Gao D . ASCT2/SLC1A5 controls glutamine uptake and tumour growth in triple-negative basal-like breast cancer. Oncogene. 2015; 35(24):3201-8. PMC: 4914826. DOI: 10.1038/onc.2015.381. View

16.

Zhao L, Rao X, Zheng R, Huang C, Kong R, Yu X . Targeting glutamine metabolism with photodynamic immunotherapy for metastatic tumor eradication. J Control Release. 2023; 357:460-471. DOI: 10.1016/j.jconrel.2023.04.027. View

17.

Ge C, Cao B, Feng D, Zhou F, Zhang J, Yang N . The down-regulation of SLC7A11 enhances ROS induced P-gp over-expression and drug resistance in MCF-7 breast cancer cells. Sci Rep. 2017; 7(1):3791. PMC: 5476638. DOI: 10.1038/s41598-017-03881-9. View

18.

Noto H, Goto A, Tsujimoto T, Noda M . Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One. 2012; 7(3):e33411. PMC: 3308971. DOI: 10.1371/journal.pone.0033411. View

19.

Szakacs G, Paterson J, Ludwig J, Booth-Genthe C, Gottesman M . Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006; 5(3):219-34. DOI: 10.1038/nrd1984. View

20.

McCreight L, Bailey C, Pearson E . Metformin and the gastrointestinal tract. Diabetologia. 2016; 59(3):426-35. PMC: 4742508. DOI: 10.1007/s00125-015-3844-9. View